Search

Your search keyword '"Peter G. M. Mol"' showing total 94 results

Search Constraints

Start Over You searched for: Author "Peter G. M. Mol" Remove constraint Author: "Peter G. M. Mol"
94 results on '"Peter G. M. Mol"'

Search Results

1. Precision medicine in regulatory decision making: Biomarkers used for patient selection in European Public Assessment Reports from 2018 to 2020

2. Modified Delphi procedure-based expert consensus on endpoints for an international disease registry for Metachromatic Leukodystrophy: The European Metachromatic Leukodystrophy initiative (MLDi)

Catalog

Books, media, physical & digital resources

4. The effect of a pharmaceutical transitional care program on rehospitalisations in internal medicine patients: an interrupted-time-series study

5. Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting

6. A Review of the Dose Justification of Phase 3 Trials to Regulatory Authorities for Drugs Intended for the Treatment of Type 2 Diabetes in Europe

7. Sex Proportionality in Pre-clinical and Clinical Trials: An Evaluation of 22 Marketing Authorization Application Dossiers Submitted to the European Medicines Agency

8. Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study

9. Evaluation of Information in Summaries of Product Characteristics (SmPCs) on the Use of a Medicine in Patients With Hepatic Impairment

11. Translating Academic Drug Discovery Into Clinical Development

12. Contribution of Real-World Evidence in European Medicines Agency's Regulatory Decision Making

13. Factors Influencing Preferences and Responses Towards Drug Safety Communications

14. Handling of New Drug Safety Information in the Dutch Hospital Setting: A Mixed Methods Approach

15. Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: Data from the swedish heart failure registry

17. Capturing Data in Rare Disease Registries to Support Regulatory Decision Making: A Survey Study Among Industry and Other Stakeholders

19. Dissemination of Direct Healthcare Professional Communications on Medication Errors for Medicinal Products in the EU: An Explorative Study on Relevant Factors

21. Inhibitor development in previously untreated patients with severe haemophilia: A comparison of included patients and outcomes between a clinical study and a registry‐based study

22. Drug Safety Issues Covered by Lay Media: A Cohort Study of Direct Healthcare Provider Communications Sent between 2001 and 2015 in The Netherlands

23. Attention for sex in COVID-19 trials: a review of regulatory dossiers

24. Correction to: Safety Communication Tools and Healthcare Professionals’ Awareness of Specific Drug Safety Issues in Europe: A Survey Study

25. Adverse drug event patterns experienced by patients with diabetes

26. Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands

27. Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study

28. Differences in medication beliefs between pregnant women using medication, or not, for chronic diseases: a cross-sectional, multinational, web-based study

29. Healthcare professionals' level of medication knowledge in Africa: a systematic review

30. Drug Registries and Approval of Drugs

31. Safety Communication Tools and Healthcare Professionals’ Awareness of Specific Drug Safety Issues in Europe: A Survey Study

32. The RIMES Statement: A Checklist to Assess the Quality of Studies Evaluating Risk Minimization Programs for Medicinal Products

33. Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?

34. Registries supporting new drug applications

35. Impact of adverse drug events and treatment satisfaction on patient adherence with antihypertensive medication - a study in ambulatory patients

36. Communication on Safety of Medicines in Europe: Current Practices and General Practitioners’ Awareness and Preferences

37. Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints

38. Effect of antithrombotic stewardship on the efficacy and safety of antithrombotic therapy during and after hospitalization

39. Authors' Reply to Ravi Jandhyala's Comment on 'Patient Registries: An Underused Resource for Medicines Evaluation: Operational Proposals for Increasing the Use of Patient Registries in Regulatory Assessments'

40. Patient Registries: An Underused Resource for Medicines Evaluation: Operational proposals for increasing the use of patient registries in regulatory assessments

41. Anticoagulant medication errors in hospitals and primary care: a cross-sectional study

42. Factors Influencing the Use of a Mobile App for Reporting Adverse Drug Reactions and Receiving Safety Information: A Qualitative Study

43. Sex Differences in Adverse Drug Reactions of Metformin

44. Interest in a Mobile App for Two-Way Risk Communication: A Survey Study Among European Healthcare Professionals and Patients

45. Smart Medication Adherence Monitoring in Clinical Drug Trials: A Prerequisite for Personalised Medicine?

46. THU-433-Availability of information in drug labels for appropriate prescribing in patients with hepatic impairment

47. Surrogate endpoints in clinical trials of chronic kidney disease progression

48. The ISoP CommSIG for Improving Medicinal Product Risk Communication

49. Adverse Drug Reaction reports for cardiometabolic drugs from sub-Saharan Africa

50. A personalised or procrustean approach to treating hypertension?